(+) Zogenix: Investor Presentation (Zogenix) - Jan 31, 2013 - "Phase 3 Efficacy Study (Study 801) Met Endpoints"; "Significant difference in chronic pain relief,Zohydro ER vs. placebo (p=0.008) based on average mean changes in daily pain intensity (Numeric Rating Scale)"; "Key secondary endpoints support Zohydro ER efficacy – Responder Rate Analysis: Significantly higher proportion of patients (%) experiencing improvement in pain relief from beginning to end of study"
P3 data • Pain
|